

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|---------------------|--|------------------|---------|------------------|
| L1 | 1064 | trotter.in. | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2007/02/21 16:25 |
| L3 | 12 | l1 and tyrosine.ti. | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB | OR | ON | 2007/02/21 16:25 |

=> b reg

FILE 'REGISTRY' ENTERED AT 11:05:24 ON 21 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
 DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta 19

L1 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
 L9 19 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 17040 ITERATIONS
 SEARCH TIME: 00.00.01

19 ANSWERS

=> d bib abs hitstr retable l18

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> b hcap

FILE 'HCAPLUS' ENTERED AT 11:05:57 ON 21 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> d bib abs hitstr retable l18

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:836790 HCAPLUS
DN 139:337988
TI Preparation of 1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine derivatives as tyrosine kinase inhibitors
IN Trotter, B. Wesley
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|-------------------|------|----------|--|--------------|--|
| PI | WO2003086315 | A2 | 20031023 | 2003WO-US12457 | 20030408 <-- | |
| | WO2003086315 | A3 | 20040108 | | | |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | CA---2480758 | A1 | 20031023 | 2003CA-2480758 | 20030408 <-- | |
| | AU2003223689 | A1 | 20031027 | 2003AU-0223689 | 20030408 <-- | |
| | EP---1496907 | A2 | 20050119 | 2003EP-0719886 | 20030408 <-- | |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | |
| | JP2005528387 | T | 20050922 | 2003JP-0583340 | 20030408 <-- | |
| | US2005227988 | A1 | 20051013 | 2004US-0510610 | 20041008 <-- | |
| PRAI | 2002US-372232P | P | 20020412 | <-- | | |
| | 2003WO-US12457 | W | 20030408 | <-- | | |
| OS | MARPAT 139:337988 | | | | | |
| GI | | | | | | |



Q = $-(CR^{1?2})_n-X-(CR^{1?2})_p-V-(R^2)_q$

AB The present invention relates to benzazocine compds. [I; wherein R1a = H, (un)substituted C1-6 alkyl, OR4; R1b = H, (un)substituted C1-6 alkyl; X = a bond, CO, O, NR4, S(O)mR4, CO2R4, CON(R4)2; R1 = H, halo, OR4, NO2, S(O)mR4, cyano, each (un)substituted C1-10 alkyl, aryl, C2-6 alkenyl, C3-10 cycloalkyl, C2-6 alkynyl, or heterocyclyl, COR4, CO2R4, CON(R4)2, S(O)mN(R4)2, N(R4)2; V = H, CF3, aryl, heterocyclyl, C3-10 cycloalkyl; R2 = H, (un)substituted C1-10 alkyl, (CR1b)tOR4, halo, cyano, NO2, CF3, (CR1b)tN(R4)2, CO2R4, COR4, SO2R4, (CR1b)tNR4(CR1b)tR5, (CR1b)tS(O)mNR4, CO2R4, NR4COR4, each (un)substituted aryl or heterocyclyl; R4 = H, each (un)substituted C1-10 alkyl, C3-10 cycloalkyl, aryl, or heterocyclyl, CF3; R5 = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n, p, q, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase, in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.


IT 615557-39-6P 615557-40-9P 615557-41-0P
615557-42-1P 615557-43-2P 615557-44-3P
615557-45-4P 615557-46-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydro(epiminomethano)benzazocine' derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-39-6 HCAPLUS


CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



⊗2 HCl


RN 615557-40-9 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 615557-41-0 HCAPLUS
 CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-
 1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 615557-42-1 HCAPLUS
 CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-
 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-43-2 HCAPLUS
 CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-
 1,2,3,4,5,6-hexahydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 615557-42-1
 CMF C21 H23 Br N2 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 615557-44-3 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 615557-45-4 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-46-5 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



IT 615557-51-2P 615557-52-3P 615557-53-4P


615557-54-5P 615557-55-6P 615557-56-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)


RN 615557-51-2 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)




RN 615557-52-3 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)




RN 615557-53-4 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-11-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 615557-54-5 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 615557-55-6 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine-3,11(2H)-dicarboxylic acid, 1,4,5,6-tetrahydro-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 615557-56-7 HCAPLUS
 CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:16:22 ON 21 FEB 2007)

FILE 'REGISTRY' ENTERED AT 09:16:31 ON 21 FEB 2007

L1 STR
 L2 0 L1

FILE 'HCAPLUS' ENTERED AT 09:23:31 ON 21 FEB 2007

L3 1 US20050227988/PN OR (US2004-510610 OR WO2003-US12457 OR US2002-
 E TROTTER B/AU
 L4 30 E5-7
 E TROTTER W/AU

FILE 'REGISTRY' ENTERED AT 09:25:24 ON 21 FEB 2007

FILE 'HCAPLUS' ENTERED AT 09:25:29 ON 21 FEB 2007

L5 TRA L3 1- RN : 36 TERMS

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 21 FEB 2007

L6 36 SEA L5
 L7 22 L6 AND N/ELS
 L8 20 NC2NC2-C6-NC7/ES OR 2492.8.1/RID
 L9 19 L1 FULL
 L10 14 L9 AND L6
 L11 5 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 10:03:22 ON 21 FEB 2007

L12 1 L10

FILE 'HCAOLD' ENTERED AT 10:03:33 ON 21 FEB 2007

L13 0 L10

FILE 'USPATFULL, USPAT2' ENTERED AT 10:03:41 ON 21 FEB 2007

L14 1 L10

FILE 'MEDLINE' ENTERED AT 10:04:31 ON 21 FEB 2007

L15 0 L10

FILE 'BIOSIS' ENTERED AT 10:04:37 ON 21 FEB 2007

L16 0 L10

L17 FILE 'EMBASE' ENTERED AT 10:04:43 ON 21 FEB 2007
0 L10

FILE 'REGISTRY' ENTERED AT 10:05:08 ON 21 FEB 2007
SAV TEM L9 J610B/A

L18 FILE 'HCAPLUS' ENTERED AT 10:05:38 ON 21 FEB 2007
1 L12 AND L3-4

L19 FILE 'REGISTRY' ENTERED AT 10:20:11 ON 21 FEB 2007
6 615557-51-2 OR 615557-52-3 OR 615557-53-4 OR 615557-54-5 OR 61

=>